Shareholder's Meeting 2011

Speech by Chairman of the Management Board
Prof. Dr. Gregor Schulz
2011 Annual Shareholders' Meeting of Biotest AG
May, 12th 2011

The spoken word applies.

(Thank you very much, Mr. Spickschen)

Ladies and gentlemen,
On my own behalf as well that of Dr. Ramroth, I'd like to welcome you to the 2011 Annual Shareholders' Meeting of Biotest AG. I would like to begin by thanking our shareholders for attending this year's meeting. We are pleased that you have decided to join Biotest in its journey and to help shape the company through your decisions.

We would also like to thank the representatives from banks and media, analysts, employees of the Biotest Group and all other guests for being here today.



“Clear focus, good prospects” – this phrase accurately describes the situation at Biotest in May 2011. Over the past twelve months, we have made important decisions to ensure the continued successful development of the company.

One important step was the sale of the Microbiological Monitoring segment, the contract for which was signed in March 2011.

The sale represents a step toward a clearly focused pharmaceutical and biotherapeutics company.

Core business position strengthened

Over the past year, we have strengthened our position in the core business in many respects.

In November 2010 we submitted the marketing authorisation dossier for Bivigam™ to the US Food and Drug Administration. This represents the final stage in the development of our new immunoglobulin. Bivigam™ has an annual sales potential of approximately USD 100 million.

The planned market launch will coincide with the expansion of plasma protein production capacity at our US subsidiary Biotest Pharmaceuticals Corporation (BPC) based in Boca Raton, Florida. Construction of the facility was completed. However, problems occurred in the automation and control systems, which led to a delay of several months in the start of production. More on that later.

We also proceed in further developing our already authorised plasma protein products, especially in terms of new indications and markets.

In addition, we expanded our plasma protein capacities in Europe. In Dreieich, construction of a new filling and packaging plant began in December of last year.

And – last but not least – important progress was made in the development of monoclonal antibodies, particularly BT-061 and BT-062.



Microbiological Monitoring – good solution found

Let me begin by giving some details on the sale of our Microbiological Monitoring segment.

The transaction comprises all activities of the Biotest HYCON product division, heipha Dr. Müller GmbH - in which we held a 51% ownership share to date - as well as all subsidiaries associated with this business.

The buyer is Merck KGaA, Darmstadt; the activities acquired will be allocated to the Merck Millipore division. The transaction remains subject to review by the relevant anti-trust authorities. We expect to finalise the transaction in the second half of the year.

The enterprise value of all transferred units is €101 million. This also includes shares held by the former minority shareholder of heipha. If we deduct these shares along with transferred liabilities and all other commitments, the expected cash flow to Biotest from the sale will range from €40 million to €50 million. Profits from the sale of €30 million to €40

million are expected. These will be reported in 2011 in results of Discontinued Operation.

Ladies and gentlemen,
The sale of the Microbiology segment represents the last step in Biotest's departure from the Diagnostics business, following the sale of Medical Diagnostics to Bio-Rad Laboratories, Inc. in 2010.

Both segments have strong products, interesting development potential and a motivated and qualified staff. However, they were simply too small for us to maintain and expand this position over the long term.

Therefore, one of our concerns was finding a strong partner for both segments. We also set great importance – let me emphasise this point– on ensuring long-term prospects for all locations and jobs.

The positive performance of Medical Diagnostics under the umbrella of Bio-Rad is confirmation that we made the right choice. We firmly believe that it will be no different in the case of Microbiology. After all, Merck Millipore is one of the largest suppliers in the field of Microbiology; the products and services of Biotest HYCON and heipha Dr. Müller are an ideal addition to its portfolio.

I am therefore fully convinced that Merck will further develop the business successfully and offer good opportunities for the staff.

At this time, I'd like to thank the entire Diagnostics staff and management for their past service and my best wishes for the future.

I would also like to thank everyone who have a share in making both transactions a success.

Biotest
From Nature for Life

Key Financial Figures 2010 / 2011

Ladies and gentlemen,
Later I will go into more detail on the progress we've made in our important projects, which I briefly mentioned in my introduction. I will also explain the focused direction of the Biotest Group.

But first I'd like to adress some key financial figures for 2010 and the first quarter of 2011.

Biotest
From Nature for Life

Sales performance 2010

Sales of the Biotest Group* (in € million)



- Sales in Continuing Operations – Plasma Proteins segment
- 2010 sales in Discontinued Operation: €51.0 million (primarily from Microbiological Monitoring segment)

* Continuing Operations

Biotest AG – Annual Shareholders' Meeting 2011 4

Key financial figures mark a year of transition

In the past year, Biotest recorded sales of €412.5 million. This represents a 5.7% increase over sales in 2009.

This figure, as well as all others that follow, relate only to Continuing Operations.

Microbiological Monitoring was treated as a Discontinued Operation in the 2010 financial statements based on our decision to sell the segment. Comparative figures for the previous year have been adjusted accordingly.

Microbiology sales and contribution to earnings are therefore not included in these figures. Profits from the sale of transfusion and transplantation diagnostics activities to Bio-Rad were also allocated to Discontinued Operation.



Earnings before interest and taxes (EBIT) for Continuing Operations in 2010 totalled €42.9 million. The nearly 25% decline compared to 2009 is primarily the result of a difficult market environment for plasma proteins. Other reasons include the increase in expenditures for research and development as scheduled as well as costs in connection with the expansion of plasma protein production at BPC. I will discuss this later in more detail.

Earnings before taxes (EBT) declined even more sharply by 37.4% to €28.4 million, reflecting the lower financial result in 2010 compared to the previous year.



This was strongly impacted by the effects of the recognition method applied to Greek government bonds, which are interest free. We therefore had to discount their value in accordance with international accounting standards. This reduced the financial result for 2010 by €5.6 million. Without this one-time recognition effect, the financial result in 2010 would have been much better than in the previous year.

For those of you wondering why Biotest holds Greek government bonds, allow me to provide a little background.

As part of its efforts to restructure public finances, the Greek government established a program under which it would give pharmaceutical companies the option of exchanging their receivables outstanding from the years 2007 to 2009 for government bonds. The bonds have a term of one to three years and are, as I mentioned, interest free. Biotest decided to participate in the program, as did most other pharmaceutical firms with eligible receivables. This was and is in our view the best way to protect our interests.

Earnings after taxes in Continuing Operations



- Earnings per ordinary share: €1.64 (2009: €2.49)
- Earnings per preference share including dividend premium: €1.70 (2009: €2.55)

Biotest AG – Annual Shareholders' Meeting 2011 7

Earnings after taxes for the Biotest Group were €19.6 million. Earnings per share were €1.64 for ordinary shares and €1.70 for preference shares.
Please remember that these figures relate only to Continuing Operations.

Earnings after taxes including Discontinued Operation



- Earnings per ordinary share: €3.12 (2009: €2.16)
- Earnings per preference share including dividend premium: €3.18 (2009: €2.22)

Biotest AG – Annual Shareholders' Meeting 2011 8

Earnings after taxes for Discontinued Operation were €19.9 million. This includes the profit from the sale of transplantation and transfusion diagnostics activities to Bio-Rad, completed in January 2010.

This item also includes earnings from the operating activities of Microbiological Monitoring. As I mentioned, the expected profit from the sale of Microbiology will be included in net income in 2011.

Taking Continuing Operations and Discontinued Operation together, earnings after taxes for 2010 total €39.5 million. This results in earnings per share of €3.12 for ordinary shares and €3.18 for preference shares.



Ladies and gentlemen,
Due to the one-time effects of the sale, Biotest is reporting very positive earnings for 2010. However, we did see a sharp decline in earnings from Continuing Operations.

This was primarily caused by the market environment for plasma protein business. At this time last year, I had already warned of the difficult regulatory conditions expected in 2010. Our expectations were confirmed.

The enlarged volume of collected plasma samples in previous years led to a sharp increase in the supply of end products. Particularly in the case of polyspecific immunoglobulins (and especially in Europe), this resulted in a considerable decline in obtainable prices by 5%. In the German clinic market, which is of special importance for us, the decline was even sharper with a price drop of around 13%

The clotting factor situation was also challenging. For example, in our bid to supply the Russian market, we were forced to make massive concessions to ensure our competitiveness.

Spending cuts in the public health care sector were a further obstacle. The price moratorium introduced in Germany in August 2010 and the increase in the mandatory discount from 6% to 16% alone cost us an additional €2.1 million last year.



Twelve months ago, I had also reported on of the industry's reaction to the oversupply and the decline in the volume of collected plasma samples. This development continued as shown in the graph. As a result, prices in some European markets began to stabilise in late 2010/early 2011.

This was aided by the intermittent absence from the immunoglobulin market of one of our competitors, Octapharma. After serious side effects, marketing authorisation in Europe was suspended in October 2010; in the US, Octapharma voluntarily recalled its products temporarily from the market. Current information indicates that Octapharma will be able to resume marketing by the middle of the year.

However, due to the long duration of supply agreements in the plasma protein business, changes in the market environment do not begin impacting sales and earnings of individual companies to a larger extent until after several months.

Additionally, the easing of pressure in major European countries and the US is being offset by a severe increase in price pressure in the other export markets, where we have seen prices fall by 20% or more.



The situation I just described is reflected in our numbers for the first quarter of 2011. We were successful in increasing sales in Continuing Operations by 3.6% compared to the same period last year to €106.5 million. However, EBIT fell short of the first quarter of 2010 by €1.6 million, coming in at €9.1 million.

There are three major reasons:
Firstly, the drop in prices in the export markets had a major impact on us. Had we been able to sell our products there at last year's prices, this alone would have resulted in an additional €6 million in sales and profit.

Secondly, in the first quarter of last year, we were not yet subject to increased mandatory discounts in Germany.

And thirdly, in plasma protein production in the US, we incurred additional unabsorbed overhead and repair costs in the first quarter, which will continue to affect us over the course of the year.

The reason is: Our new production plant at BPC was completed. However, problems arose in the automation of individual process steps in production.

This led to higher unabsorbed overhead costs, the impact of which will be felt throughout the year, beyond just the first quarter. Although production of Nabi HB will resume later this year and we will still be able to manufacture additional Bivigam™ consistency batches, the costs for the entire year will total to €7 million to €8 million.

This will have a direct and large-scale negative impact on our 2011 earnings.

Unfortunately, due to these technical difficulties, marketing authorisation for Bivigam™ will be delayed. We now expect to receive it during the first half of 2012 and not by the end of 2011 as originally planned.
I would like to emphasise that this delay is associated exclusively with technical problems in production. Otherwise, the processing of our application by the FDA has thus far progressed quickly and smoothly.

You are probably wondering why a German company with a fully functioning production operation in Germany is reporting problems with an automation system. Please remember that the project at our Florida subsidiary BPC is not new construction, nor is it a copy of the German facility, but an expansion of an existing production system. This required to integrate existing functional units and the existing operating system with new system components as well as a new fully automated cleaning system.
In addition, new control software had to be developed. To do this, we hired the same American engineering firm that had programmed the last control software. On starting up the system, however, we noticed that the selected matrix structure of the automation software was not capable of controlling the existing function groups, the new cleaning program interfaces and the more than 4,000 new control elements to ensure stable, error-free production. The intensive work required to correct these errors and the necessary testing that always accompanies such work has led to these delays.

For detailed information on our performance in the first quarter of 2011, please see our Quarterly Report published on 10 May 2011.

Earnings and sales targets for 2011

Influencing factors:

- Poor price performance in Q1 in markets outside Europe
- Increased future uncertainty
- Additional costs of €7 to €8 million incurred at BPC

Earnings targets lowered accordingly

Sales targets confirmed

(previous targets for 2011: sales and earnings growth of 1-2%)

Biotest AG – Annual Shareholders' Meeting 2011 12

In light of this development, we feel the need to lower our original EBIT targets for the year. Our original estimates called for a slight increase of 1% to 2%. From today's perspective, EBIT is expected to fall short of this target by €7 million to €8 million. In the case of sales, we continue to expect 1% to 2% growth compared to 2010.

Once again, I'd like to remind you that the targets also refer only to Continuing Operations. The expected profit from the sale of the Microbiological Monitoring segment are excluded from these targets as are any possible proceeds from a licensing agreement for our monoclonal antibodies.

Biotest: Direction and Strategy

Ladies and gentlemen,

After several years of extremely profitable growth, Biotest experienced a dent in operating income in 2010/11.

We had predicted a stormy market environment early on – earlier, in fact, than many in our industry. However, the extent and duration of the market adjustment caught also us by surprise.

Despite the stabilising trends in the market, a certain degree of uncertainty remains with regard to future developments. In light of this, we have adjusted our earnings targets.

Strategic performance: a successful 2010

Ladies and gentlemen,
In view of the reduction in our short-term earnings targets, we should not forget about the important progress made in the last twelve months in ensuring the long-term prospects of Biotest.

Our strategic focal points are: increased focus on the core business, the internationalisation of this business and research and development.

The deconsolidation of our diagnostics business has allowed us to further focus our mission.

Biotest 2011 – clear focus on Plasma Proteins and Biotherapeutics



Biotest is now focused on its core business of plasma proteins and biotherapeutics. We are active in the therapeutic indication areas of clinical immunology, haematology as well as intensive care and emergency medicine. We have strong products in all three areas, as well as an impressive development pipeline.



In clinical immunology, we offer Intratect®, one of the leading polyspecific immunoglobulins in the market. In the area of hyperimmunoglobulins, we are prominent experts in hepatitis B prophylaxis. With Hepatect® CP and Zutectra® in Europe and Nabi® HB in the US, we are a leading supplier in the indication of reinfection prophylaxis following hepatitis B-related liver transplantation.

Other hyperimmunoglobulins include Cytotect® CP, Biotest Megalotect® and Varitect®. These are used in the prophylaxis and treatment of cytomegalovirus or zoster virus infections.

In the haematology area, we have Haemoctin® and Haemonine® for treatment of haemophilia A and B.

Finally, we are represented in the intensive care and emergency medicine market by Pentaglobin® for serious bacterial infections, the prothrombin complex Cofact®, our albumin preparations and Biseko®.



Our product range in all three areas is expanding with targeted new product developments and improvements in existing ones. In case of our plasma proteins, for example, we are expanding into new indications and markets for already marketed drugs and are seeking marketing approval for new preparation.

Our Biotherapeutics segment includes monoclonal antibodies: They complement our product portfolio.
BT-061 and BT-063 in clinical immunology and BT-062 in haematology.

Comparable or related therapeutic indications allow us to leverage our expertise, experience, network and resources from the plasma protein business into biotherapeutics as well.



Biotest – foremost in complex diseases

Ladies and gentlemen,
Biotest has special expertise and a preeminent market position in complex diseases of the immune system and the blood.

In the case of plasma proteins, hyperimmunoglobulins used for specific medical conditions and special products currently account for about 28% of total sales – a proportion no other competitor has achieved. As hyperimmunoglobulins are specialty products, their prices are higher and more stable than those of polyspecific immunoglobulins.

Consequently, we are working to expand our position in this area.

I would now like to explain the current status of our major development projects. Let me begin with plasma proteins, after which I'll talk about monoclonal antibodies.

Plasma Protein R&D – marketing authorisation for Bivigam™ as a milestone

In November 2010, our US subsidiary Biotest Pharmaceuticals Corporation (BPC) submitted the marketing authorisation dossier for Bivigam™ to the US Food and Drug Administration. Marketing

authorisation is now expected for the first half of 2012, with initial sales of Bivigam™ beginning in the middle of next year.

Bivigam™ is a polyspecific immunoglobulin that is very similar in composition and product characteristics to another one of our products, Intratect®. It was developed especially for the US market and offers significant sales potential for Biotest. Based on current prices, annual sales of up to USD 100 million are expected.

The marketing authorisation of Bivigam™ will allow Biotest to significantly expand its presence in the world's largest and most attractive market for immunoglobulins – a critical element in our long-term growth strategy.

At the same time, we are moving Intratect® into new markets, such as through marketing authorisation in France and development of a 10% solution for outpatient treatment.



In Europe, we are working to further strengthen our expertise in the area of hepatitis B prophylaxis. Our immunoglobulin Fovepta™, which is designed for administration to newborns, is in the final development phase. It represents a new addition to our range of products for this indication, which include Hepatect® CP and Zutectra®, both authorised in Europe, and Nabi® HB produced by BPC. In the first half of 2012, we plan to continue the clinical development of Civacir™, a hyperimmunoglobulin against hepatitis C, after optimising the manufacturing process and product specifications.



Those of you who have been following Biotest for a long time know that we have been working for a while now on a major study with Cytotect® CP. Our goal is to deliver statistical evidence of the efficacy of our preparation in preventing the transfer of cytomegalovirus to unborn children from pregnant mothers infected for the first time. A reduced incidence of deformities and neurological complications in newborns is also expected. Data became available from an interim analysis in early 2011 that show clear evidence of the efficacy of Cytotect® CP.

Based on these results, we have decided to continue the project. More than 7,400 pregnant women have already been screened, with the number expected to exceed 10,000 by the end of the study. This high number of participants is necessary, as we can only accept women into the study who were infected with the virus for the first time during their pregnancy.



Finally, with regard to our plasma protein development projects, I'd like to draw your attention to our IgM concentrate and fibrinogen.

IgM concentrate is a successor drug to Pentaglobin®, which is used to treat severe bacterial infections. It differs from Pentaglobin® in its higher proportion of IgM immunoglobulins and is thus functionally more active.

It offers an additional advantage over Pentaglobin® in that it can be produced using intermediates manufactured in-house. This eliminates the need to purchase these intermediates from external sources as in the past and allows us to better utilise processed plasma.

In the third quarter of 2011, we plan to launch a clinical trial of IgM concentrate for the indication of severe community-acquired pneumonia.

Fibrinogen is a protein that halts or prevents haemorrhage in the body.

Biotest is developing a fibrinogen preparation to be used as replacement therapy for fibrinogen deficiency in the case of severe haemorrhage and haemorrhage complications, such as in the case of heart surgery or severe injury. The market for this indication is currently growing quite dynamically, as a diagnostic procedure for the proper detection of fibrinogen deficiency has only recently become available.

Currently, there is only one competitive product for this indication being distributed throughout Europe and the US. Biotest's fibrinogen will offer significant advantages over the existing product in terms of use.

The clinical trial is scheduled to begin in early 2012. The annual sales potential for Biotest is around €35 million.



Biotherapeutics – proven efficacy

Ladies and gentlemen,
Biotest is also expanding its expertise in the areas of immunology and haematology with monoclonal antibodies.

Our current pipeline includes three monoclonal antibodies: BT-061, BT-062 and BT-063. Here you see an overview of the respective lead indications: rheumatoid arthritis and psoriasis for BT-061, multiple myeloma for BT-062 and systemic lupus erythematosus in the case of BT-063.

All three monoclonal antibodies in these lead indications are currently in the clinical development phase. In the case of both BT-061 and BT-062, we have clear signs of evidence of clinical efficacy from current or completed studies. In addition, all three antibodies have additional potential therapeutic indications ("upside indications"). We are currently examining whether development in these indications is worthwhile for Biotest.



Last year, I presented preliminary data from Phase II study No. 971, which was still ongoing at that time. The study tested BT-061 in combination with methotrexate, the most commonly used basic treatment for rheumatoid arthritis. We now have the final data from this study, which confirm our claim from twelve months ago: Patients administered BT-061 in combination with methotrexate during the study showed much better improvement in their clinical picture than the control group.

In addition, as you see on this chart, the improvement exceeds the values obtained after a comparable treatment period with already authorised biotherapeutics (average values from independent studies).

The abbreviations ACR 50 and ACR 70 in the chart stand for a 50% and 70% improvement, respectively, in various disease symptoms.

This is even more noteworthy given the fact that, based on current knowledge, a full effect of such drugs is only demonstrated after three to four months. However, the treatment period in this study lasted only eight weeks, with analyse taking place in week nine. We are therefore confident that the differences will be even greater in studies with longer administration periods.



Ladies and gentlemen,
The competitive position of our monoclonal antibodies is the subject of many of the questions we receive. This is especially true in the case of BT-061 for rheumatoid arthritis, as there are a number of projects in this indication that on first glance appear to be competitive. Is there a risk of a competitor developing a better product?

We believe this risk to be rather unlikely, as BT-061 has a generally different mechanism of action than all other treatments currently in development. In addition, only a few projects have passed clinical phase II.

Both factors – the unique mechanism of action and the fact that BT-061 is one of the most advanced new treatments for rheumatoid arthritis – are reason enough to continue to classify the potential of BT-061 as very positive. Above all, the special mode of action of BT-061 should ensure less side effects than competing projects and already marketed products.

Our confident assessment is also supported by the fact that a third of all originally competitive projects have meanwhile been stopped due to poor tolerability or lack of efficacy.

Previous data from the clinical development phase indicate the efficacy of BT-061 for psoriasis and BT-062 for the lead indication of multiple myeloma, an incurable type of blood cancer.

However, in the case of such innovative development projects as our monoclonal antibodies, there is always a risk of failure. It is therefore particularly significant that all three Biotest antibodies have consistently demonstrated a high level of tolerability in previous studies.

Research and development – a top priority for Biotest



Ladies and gentlemen,
Research and development is critically important to Biotest. Thus, our efforts in this area are large-scale – including big financial investments.

In the past three years, our R&D expenses have totalled more than 10% of sales each year. We have invested extensively in Plasma Proteins and Biotherapeutics and will continue to do so in the future. In 2010, the total R&D expenditure for Plasma Proteins and Biotherapeutics was just under €50 million.



As most of you know, we plan to continue independently developing our monoclonal antibodies until Phase III, at which time we will partner with global pharmaceutical or biotech companies. Our concept calls for granting our partner global development and distribution rights. If marketing authorisation is granted, Biotest would co-market the drug in some regions, particularly Europe, with the partner. In other international markets such as the US or Asia, the partner would market the drug exclusively and pay Biotest corresponding licensing fees.

We are currently in intense negotiations regarding a partnership contract for BT-061. We are already in agreement on several key aspects of collaboration with potential partners. Please understand that I am unable to offer any further details until the contract is signed.

Those of you who have been following Biotest reports closely will remember an interview I gave last autumn, in which I discussed the advanced negotiations and possible signing of a contract within the coming months.

At the time of the interview, we were in fact in the middle of intense negotiations. However, drafting a detailed agreement is a highly complex task. After all, our goal is to structure a contract that best serves the interests of both sides for a period of many years.

I admit that I had expected the process to progress more quickly. However, I'm afraid I was a bit too optimistic.

Our partnering motto continues to be "thoroughness before speed". Our primary goal is to ensure that the contract is structured in a way that benefits Biotest as much as possible. In the meantime, clinical development will continue independently as planned.

Expansion of capacities and sales structures

Ladies and gentlemen,
Research and development is one of the pillars on which the long term success of Biotest rests. The second is the further expansion of our structures and capacities.

In the past five years, Biotest invested more than €130 million in its plants. As a result, today we are at the cutting edge of production technology in Europe and the US. In the area of biotherapeutics, we also cover the entire value chain by producing our own monoclonal antibodies at BPC.

For the past several years, the expansion of plasma protein capacities at BPC has been one of our focuses. In the coming years, the emphasis will be on our capital expenditure in Europe.

In Dreieich, we began construction of a new packaging and filling plant, which is scheduled for completion in 2013. We are thus adjusting our capacities in this area to handle higher production volumes. We plan to invest €25 million in this project alone. Overall, the 2011 budget calls for capital expenditure of around €35 million.

The expansion of our capacities coincides with the further development of our international sales structures. In the US, for example, we are in the process of gradually building teams to market Bivigam™.

In January 2011, we also acquired all shares in our former distributor for the Brazilian market. We will use this new subsidiary as a platform for additional growth in the Brazilian market and the gradual expansion of our activities to other Latin American countries.

The takeover of an already established company in the market is another step on Biotest's path of organic growth. We continuously evaluate potential acquisitions as they arise to see if they are a strategic fit for our activities, and we are in a position to act quickly on any opportunities if necessary.

Ladies and gentlemen,
I hope that my statements have provided a clear overview of where Biotest stands today and the direction in which our company is evolving.

Despite a difficult market environment, we can look back on, in my view, a successful 2010:

- Progress was made on all major strategic projects within the Group.

- We made important progress in the development of both Plasma Proteins and Biotherapeutics.

- We took additional steps to adjust our capacities.

- With the sale of our diagnostics business to Bio-Rad Inc. and Merck KGaA, we are now more focused on our role as a supplier of pharmaceuticals in the areas of clinical immunology, haematology and intensive and emergency medicine. Under the new ownership structure, the units sold will be better able to exercise their strengths.

All of this creates a good starting position for Biotest to take full advantage of the noticeable recovery in the market for plasma proteins. We expect the supply to continue to ease over the course of the year. However, as I mentioned at the beginning, we do not expect this to significantly impact our earnings until 2012.

At this time, I'd like to thank the entire staff of the Group for their commitment over the last twelve months. I hope and believe that the feeling is mutual.



Ladies and gentlemen,
The publishing of our quarterly results and the announcement of our adjusted earnings targets in the past few days have left their mark on the price of Biotest's stock. Nevertheless, in the past twelve months we were able to increase the price of ordinary shares of Biotest by 41% and preference shares by 47%, thus outperforming the SDAX.

I firmly believe that the good prospects of the Biotest Group will continue to be reflected in our stock price.

Dividend recommendation



- Recommendation to ASM regarding appropriation of 2010 profits:
- Net profit: € 22,653,652.94
- Payout: € 4,764,858.48
- Dividend:

  €0.38 per ordinary share
  €0.44 per preference share

Biotest AG – Hauptversammlung 2011 32

Biotest's goal is to allow its shareholders to share in the success of the company through a reliable and stable dividend policy. For the past financial year, the Board of Management and Supervisory Board have recommended to the Annual Shareholders' Meeting, as per Item 2 on the agenda, a dividend payment of €0.38 per ordinary share and €0.44 per preference share. The resulting payout is a good 10% higher than last year's.

We believe that this recommendation adequately takes into account both our earnings performance in Continuing Operations as well as the extraordinary income from the sale of Medical Diagnostics.

Clear Focus – Good Prospects

Thank you for your attention!

Ladies and Gentlemen,
Biotest in May 2011 – is a clearly focused pharmaceutical company with attractive products and a development pipeline rife with opportunities. Our task for the future will now be to utilise our potential and convert it into profitable business.

Dr. Ramroth and I would like to thank you for your support and trust in Biotest. We look forward to continuing this journey with you by our side.

Thank you very much for your attention.